Arrayit Corporation Aces Three Consecutive Rounds of Proficiency Testing with the College of American Pathologists

October 8, 2018

Sunnyvale, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, reports that its clinical team aced three consecutive rounds of blinded-specimen Proficiency Testing (PT) with the College of American Pathologists (CAP). The SC-2017, SA-2018 and SB-2018 triannual CAP Diagnostic Immunology Surveys require highly quantitative measurements of immunoglobulin E (IgE), the antibody molecules measured by the company’s finger stick allergy microarray tests. Arrayit’s highly accurate PT performance showcases the robustness of the company’s proprietary allergy testing platform and reagents, which are increasingly being leveraged by doctors as a tool to diagnose and treat allergy and asthma.

Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, signed allergy testing contracts with a consortium of 178 medical clinics, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS), and reported the sale and shipment of clinical instrumentation to the FDA. Consistent high-level proficiency testing performance, supervised by the rigorous and impartial CAP, facilitates reimbursement by private and government allergy test payors.

Chief Executive Officer Rene Schena states, “Proficiency testing excellence by the clinical personnel in our California-based Clinical Laboratory Improvement Amendments (CLIA) laboratory illustrates our commitment to providing the most accurate and valuable healthcare information to doctors for their patients. Our value-based medicine approach, coupled with rapid and non-invasive allergy testing technology, has transformative implications for the health and wellness marketplaces.”

About Arrayit Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.

Safe Harbor Statement We have identified forward-looking statements by using words such as “expect”, “believe”, and “should”. Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s public filings.

CONTACT Public Relations Arrayit Corporation Tel: 408-744-1331 Email: arrayit@arrayit.com Web: www.arrayit.com

CONTACT Public Relations Arrayit Corporation Tel: 408-744-1331 Email: arrayit@arrayit.com Web: www.arrayit.com

Update hourly